California State Teachers Retirement System Acquires 59,967,294 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

California State Teachers Retirement System grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 30,461.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 60,164,157 shares of the biopharmaceutical company’s stock after buying an additional 59,967,294 shares during the quarter. California State Teachers Retirement System owned 0.45% of Alnylam Pharmaceuticals worth $18,111,216,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. MV Capital Management Inc. purchased a new position in Alnylam Pharmaceuticals in the fourth quarter worth about $25,000. HM Payson & Co. purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $27,000. Golden State Wealth Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 36 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $29,000. Finally, Manchester Capital Management LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 600.0% in the 4th quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 72 shares during the period. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $266.11 on Tuesday. The firm has a fifty day moving average price of $258.70 and a 200-day moving average price of $290.98. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. The firm has a market capitalization of $35.61 billion, a P/E ratio of 49.46 and a beta of 0.31. Alnylam Pharmaceuticals, Inc. has a 12-month low of $197.81 and a 12-month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. The company had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.32 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The firm’s revenue for the quarter was up 66.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.51) EPS. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.71 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ALNY shares. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, July 31st. Barclays dropped their price objective on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating for the company in a research note on Monday, August 3rd. Royal Bank Of Canada reduced their target price on shares of Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. JPMorgan Chase & Co. lowered their target price on shares of Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Finally, Morgan Stanley cut their price target on shares of Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating on the stock in a report on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $386.14.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.